{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T05:52:30Z","timestamp":1770616350527,"version":"3.49.0"},"reference-count":9,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T00:00:00Z","timestamp":1490659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Med Imag Rad Onc"],"published-print":{"date-parts":[[2017,8]]},"abstract":"Summary<\/jats:title>Gallium\u201068 prostate specific membrane antigen ligand (Ga\u201068 PSMA<\/jats:styled-content>) positron emission tomography\/computed tomography (PET<\/jats:styled-content>\/CT<\/jats:styled-content>) scanning is emerging as a useful imaging modality for the staging of suspected and known recurrent or metastatic prostate cancer and in staging of newly diagnosed higher grade prostate cancer. However, we have observed at our institution that in some cases of the more aggressive ductal variant, Ga\u201068 PSMA<\/jats:styled-content> uptake has sometimes been poor compared with prominent 18\u2010flourodeoxyglucose (F\u201018 FDG<\/jats:styled-content>) avidity seen in F\u201018 FDG PET<\/jats:styled-content>\/CT<\/jats:styled-content>, which would suggest that FDG PET<\/jats:styled-content>\/CT<\/jats:styled-content> scans are important in staging of ductal pattern prostate cancer.<\/jats:p>","DOI":"10.1111\/1754-9485.12605","type":"journal-article","created":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T05:03:01Z","timestamp":1490677381000},"page":"503-505","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Flourodeoxyglucose positron emission tomography scan may be helpful in the case of ductal variant prostate cancer when prostate specific membrane antigen ligand positron emission tomography scan is negative"],"prefix":"10.1111","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4681-1891","authenticated-orcid":false,"given":"Louise M","family":"McEwan","sequence":"first","affiliation":[{"name":"Wesley Medical Imaging The Wesley Hospital Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Wong","sequence":"additional","affiliation":[{"name":"Wesley Medical Imaging The Wesley Hospital Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Yaxley","sequence":"additional","affiliation":[{"name":"Wesley Urology Clinic The Wesley Hospital Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,3,28]]},"reference":[{"key":"e_1_2_4_2_1","volume-title":"RANZCR Annual Scientific Meeting","author":"Brown N","year":"2016"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-012-2298-2"},{"issue":"1","key":"e_1_2_4_4_1","doi-asserted-by":"crossref","first-page":"O10","DOI":"10.1186\/1470-7330-14-S1-O10","article-title":"PSMA ligands for diagnosis and therapy of prostate cancer","volume":"14","author":"Haberkorn U","year":"2014","journal-title":"Cancer Imaging"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000000290"},{"key":"e_1_2_4_6_1","first-page":"3192","article-title":"Five different anti\u2010prostate\u2010specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor\u2010associated neovasculature","volume":"59","author":"Chang SS","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.830"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2011-0519-RA"},{"key":"e_1_2_4_9_1","first-page":"393","article-title":"Ductal adenocarcinoma of the prostate","volume":"2","author":"Shazer RL","year":"2004","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22644"}],"container-title":["Journal of Medical Imaging and Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1754-9485.12605","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1754-9485.12605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T13:37:53Z","timestamp":1696253873000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1754-9485.12605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,28]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1111\/1754-9485.12605"],"URL":"https:\/\/doi.org\/10.1111\/1754-9485.12605","archive":["Portico"],"relation":{},"ISSN":["1754-9477","1754-9485"],"issn-type":[{"value":"1754-9477","type":"print"},{"value":"1754-9485","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,28]]},"assertion":[{"value":"2016-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}